Cite
HARVARD Citation
Prince, H. et al. (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 390 (10094), pp. 555-566. [Online].